Literature DB >> 22628487

Quantitative computerized two-point correlation analysis of lung CT scans correlates with pulmonary function in pulmonary sarcoidosis.

Barbaros Selnur Erdal1, Elliott D Crouser2, Vedat Yildiz3, Mark A King4, Andrew T Patterson4, Michael V Knopp4, Bradley D Clymer5.   

Abstract

BACKGROUND: Chest CT scans are commonly used to clinically assess disease severity in patients presenting with pulmonary sarcoidosis. Despite their ability to reliably detect subtle changes in lung disease, the utility of chest CT scans for guiding therapy is limited by the fact that image interpretation by radiologists is qualitative and highly variable. We sought to create a computerized CT image analysis tool that would provide quantitative and clinically relevant information.
METHODS: We established that a two-point correlation analysis approach reduced the background signal attendant to normal lung structures, such as blood vessels, airways, and lymphatics while highlighting diseased tissue. This approach was applied to multiple lung fields to generate an overall lung texture score (LTS) representing the quantity of diseased lung parenchyma. Using deidentified lung CT scan and pulmonary function test (PFT) data from The Ohio State University Medical Center's Information Warehouse, we analyzed 71 consecutive CT scans from patients with sarcoidosis for whom simultaneous matching PFTs were available to determine whether the LTS correlated with standard PFT results.
RESULTS: We found a high correlation between LTS and FVC, total lung capacity, and diffusing capacity of the lung for carbon monoxide (P < .0001 for all comparisons). Moreover, LTS was equivalent to PFTs for the detection of active lung disease. The image analysis protocol was conducted quickly (< 1 min per study) on a standard laptop computer connected to a publicly available National Institutes of Health ImageJ toolkit.
CONCLUSIONS: The two-point image analysis tool is highly practical and appears to reliably assess lung disease severity. We predict that this tool will be useful for clinical and research applications.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22628487      PMCID: PMC4511386          DOI: 10.1378/chest.11-2027

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  18 in total

1.  Quantitative CT indexes in idiopathic pulmonary fibrosis: relationship with physiologic impairment.

Authors:  Alan C Best; Anne M Lynch; Carmen M Bozic; David Miller; Gary K Grunwald; David A Lynch
Journal:  Radiology       Date:  2003-06-11       Impact factor: 11.105

Review 2.  CT evaluation of diffuse infiltrative lung disease: dose considerations and optimal technique.

Authors:  John R Mayo
Journal:  J Thorac Imaging       Date:  2009-11       Impact factor: 3.000

Review 3.  Pulmonary function testing in idiopathic interstitial pneumonias.

Authors:  Fernando J Martinez; Kevin Flaherty
Journal:  Proc Am Thorac Soc       Date:  2006-06

4.  High-resolution CT-derived measures of lung density are valid indexes of interstitial lung disease.

Authors:  P G Hartley; J R Galvin; G W Hunninghake; J A Merchant; S J Yagla; S B Speakman; D A Schwartz
Journal:  J Appl Physiol (1985)       Date:  1994-01

5.  Computer-aided detection of early interstitial lung diseases using low-dose CT images.

Authors:  Sang Cheol Park; Jun Tan; Xingwei Wang; Dror Lederman; Joseph K Leader; Soo Hyung Kim; Bin Zheng
Journal:  Phys Med Biol       Date:  2011-01-25       Impact factor: 3.609

6.  Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.

Authors:  Robert P Baughman; Marjolein Drent; Mani Kavuru; Marc A Judson; Ulrich Costabel; Roland du Bois; Carlo Albera; Martin Brutsche; Gerald Davis; James F Donohue; Joachim Müller-Quernheim; Rozsa Schlenker-Herceg; Susan Flavin; Kim Hung Lo; Barry Oemar; Elliot S Barnathan
Journal:  Am J Respir Crit Care Med       Date:  2006-07-13       Impact factor: 21.405

Review 7.  Assessing pulmonary disease and response to therapy: which test?

Authors:  Greg Keir; Athol U Wells
Journal:  Semin Respir Crit Care Med       Date:  2010-07-27       Impact factor: 3.119

Review 8.  Pulmonary function tests in connective tissue disease.

Authors:  Athol U Wells
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

9.  Short-term reproducibility of computed tomography-based lung density measurements in alpha-1 antitrypsin deficiency and smokers with emphysema.

Authors:  S B Shaker; A Dirksen; L C Laursen; N Maltbaek; L Christensen; U Sander; N Seersholm; L T Skovgaard; L Nielsen; A Kok-Jensen
Journal:  Acta Radiol       Date:  2004-07       Impact factor: 1.990

Review 10.  Clinical use of biomarkers of survival in pulmonary fibrosis.

Authors:  Michiel Thomeer; Jan C Grutters; Wim A Wuyts; Stijn Willems; Maurits G Demedts
Journal:  Respir Res       Date:  2010-06-28
View more
  6 in total

1.  Radiology and Enterprise Medical Imaging Extensions (REMIX).

Authors:  Barbaros S Erdal; Luciano M Prevedello; Songyue Qian; Mutlu Demirer; Kevin Little; John Ryu; Thomas O'Donnell; Richard D White
Journal:  J Digit Imaging       Date:  2018-02       Impact factor: 4.056

2.  Assessment of lung involvement in sarcoidosis - the use of an open-source software to quantify data from computed tomography.

Authors:  Tomaz Urbankowski; Lucyna Opoka; Paweł Wojtan; Rafal Krenke
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2017-04-28       Impact factor: 0.670

3.  Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis.

Authors:  Regina Aleksonienė; Ingrida Zeleckienė; Mindaugas Matačiūnas; Roma Puronaitė; Laimutė Jurgauskienė; Radvilė Malickaitė; Edita Strumilienė; Vygantas Gruslys; Rolandas Zablockis; Edvardas Danila
Journal:  J Thorac Dis       Date:  2017-01       Impact factor: 2.895

4.  Design, rationale, and baseline characteristics of a pilot randomized clinical trial of nicotine treatment for pulmonary sarcoidosis.

Authors:  Erinn M Hade; Rachel M Smith; Daniel A Culver; Elliott D Crouser
Journal:  Contemp Clin Trials Commun       Date:  2020-10-07

5.  Is there an added value of cardiopulmonary exercise testing in sarcoidosis patients?

Authors:  Rik G J Marcellis; Antoine F Lenssen; Geeuwke J de Vries; Robert P Baughman; Chris P van der Grinten; Johny A Verschakelen; Jolanda De Vries; Marjolein Drent
Journal:  Lung       Date:  2012-11-09       Impact factor: 2.584

6.  A Pilot Randomized Trial of Transdermal Nicotine for Pulmonary Sarcoidosis.

Authors:  Elliott D Crouser; Rachel M Smith; Daniel A Culver; Mark W Julian; Karen Martin; Joanne Baran; Christopher Diaz; Barbaros Selnur Erdal; Erinn M Hade
Journal:  Chest       Date:  2021-05-23       Impact factor: 10.262

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.